The Mikaela Naylon Give Kids a Chance Act of 2025 aims to enhance the development and approval of treatments for pediatric cancers by improving the Food and Drug Administration's (FDA) authority to conduct targeted investigations for children. The legislation focuses on ensuring that effective cancer treatments are available for young patients by mandating that drug companies design studies specifically for children, using either new drugs or combinations of existing ones that have shown efficacy in adult cancers.